Trial reportJournal of nuclear medicine : official publication, Society of Nuclear Medicine2013
11C-acetate PET/CT before radical prostatectomy: nodal staging and treatment failure prediction.
Trial report in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Radiopharmaceuticals for PET and SPECT Imaging: A Literature Review over the Last Decade.International journal of molecular sciences · 2022Pooled it
- The Role of Magnetic Resonance Imaging and Positron Emission Tomography/Computed Tomography in the Primary Staging of Newly Diagnosed Prostate Cancer: A Systematic Review of the Literature.European urology oncology · 2021Pooled it
- A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2015Trial
- Outcomes of pelvic radiotherapy with boost strategies in high nodal-risk prostate cancer: A phase 2 prospective trial.Clinical and translational radiation oncology · 2026Article
- Spatial metabolomics informs the use of clinical imaging for improved detection of cribriform prostate cancer.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Targeted Molecular Imaging as a Biomarker in Urologic Oncology.The Urologic clinics of North America · 2023Review
- Molecular Imaging in Primary Staging of Prostate Cancer Patients: Current Aspects and Future Trends.Cancers · 2021Review
- Preoperative 68Ga-PSMA PET/CT defines a subgroup of high-risk prostate cancer patients with favorable outcomes after radical prostatectomy and lymph node dissection.Prostate cancer and prostatic diseases · 2021Article
- Comparison of cross-sectional imaging techniques for the detection of prostate cancer lymph node metastasis: a critical review.Translational andrology and urology · 2020Review
- Carbon Flux as a Measure of Prostate Cancer Aggressiveness: [International journal of medical sciences · 2020Article
- Biological principles and clinical application of positron emission tomography-tracers in prostate cancer: a review.Prostate international · 2019Review
- Novel Imaging in Detection of Metastatic Prostate Cancer.Current oncology reports · 2019Review
- Histological Validation of 11Carbon-Acetate Positron Emission Tomography/Computerized Tomography in Detecting Lymph Node Metastases in Prostate Cancer.The Journal of urology · 2019Article
- Imaging as a Personalized Biomarker for Prostate Cancer Risk Stratification.Diagnostics (Basel, Switzerland) · 2018Review
- MRI andRadiology and oncology · 2018Article
- Optimization of PET reconstruction algorithm, SUV thresholding algorithm and PET acquisition time in clinical 11C-acetate PET/CT.PloS one · 2018Article
- Current Imaging Techniques for Lymph Node Staging in Prostate Cancer: A Review.Frontiers in surgery · 2018Review
- Functional and Targeted Lymph Node Imaging in Prostate Cancer: Current Status and Future Challenges.Radiology · 2017Review
- Lymph node imaging in initial staging of prostate cancer: An overview and update.World journal of radiology · 2017Review
- Positron emission tomography (PET) in primary prostate cancer staging and risk assessment.Translational andrology and urology · 2017Review
Corrections and comments
- Commented on by
Authors and funding
11 authors.
Funding
Abstract
unlabelledDespite early detection programs, many patients with prostate cancer present with intermediate- or high-risk disease. We prospectively investigated whether (11)C-acetate PET/CT predicts lymph node (LN) metastasis and treatment failure in men for whom radical prostatectomy is planned.
methods107 men with intermediate- or high-risk localized prostate cancer and negative conventional imaging findings underwent PET/CT with (11)C-acetate. Five underwent LN staging only, and 102 underwent LN staging and prostatectomy. PET/CT findings were correlated with pathologic nodal status. Treatment-failure-free survival was estimated by the Kaplan-Meier method. The ability of PET/CT to predict outcomes was evaluated by multivariate Cox proportional hazards analysis.
resultsPET/CT was positive for pelvic LN or distant metastasis in 36 of 107 patients (33.6%). LN metastasis was present histopathologically in 25 (23.4%). The sensitivity, specificity, and positive and negative predictive values of PET/CT for detecting LN metastasis were 68.0%, 78.1%, 48.6%, and 88.9%, respectively. Treatment failed in 64 patients: 25 with metastasis, 17 with a persistent postprostatectomy prostate-specific antigen level greater than 0.20 ng/mL, and 22 with biochemical recurrence (prostate-specific antigen level > 0.20 ng/mL after nadir) during follow-up for a median of 44.0 mo. Treatment-failure-free survival was worse in PET-positive than in PET-negative patients (P < 0.0001) and in those with false-positive than in those with true-negative scan results (P < 0.01), suggesting that PET may have demonstrated nodal disease not removed surgically or identified pathologically. PET positivity independently predicted failure in preoperative (hazard ratio, 3.26; P < 0.0001) and postoperative (hazard ratio, 3.07; P = 0.0001) multivariate models.
conclusionIn patients planned for or completing prostatectomy, (11)C-acetate PET/CT detects LN metastasis not identified by conventional imaging and independently predicts treatment-failure-free survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.